Stable transfection of estrogen receptor-alpha suppresses expression of cyclooxygenase-2 and vascular endothelial growth factor-C in MDA-MB-231 breast cancer cells

Chinese Medical Journal

Volumn 123, Issue 15, 2010, Pages 1989-1994

  Zhang, Hui ^a   Lin, Ying ^a   Xiao, Ying ^a   Wang, San Ming ^a   Liu, Xiang Xia ^a   Wang, Shen Ming ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Breast neoplasms; Cyclooxygenase 2; Estrogen receptor alpha; Vascular endothelial growth factor C

Indexed keywords

CYCLOOXYGENASE 2; DNA; ESTROGEN RECEPTOR ALPHA; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; VASCULOTROPIN C;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PLASMID; PROTEIN EXPRESSION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; HUMANS; POLYMERASE CHAIN REACTION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 77956122287     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.15.007     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Yao C, Lin Y, Ye CS, Bi J, Zhu YF, Wang SM. Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer. Chin Med J 2007; 120: 1766-1772.
3. Zhou B, Yang DQ, Xie F. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma. Chin Med J 2008; 121: 387-391.
4. Liu Q, Li JG, Zheng XY, Jin F, Dong HT. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. Chin Med J 2009; 122: 2763-2769.
5. Mylona E, Alexandrou P, Mpakali A, Giannopoulou I, Liapis G, Markaki S, et al. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. Eur J Surg Oncol 2007; 33: 294-300.
6. Nakamura Y, Yasuoka H, Tsujimoto M, Imabun S, Nakahara M, Nakao K, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 2005; 91: 125-132.
7. Timoshenko AV, Rastogi S, Lala PK. Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br J Cancer 2007; 97: 1090-1098.
8. Ristimaki A, Sivula A, Lundin J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 632-635.
9. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 2003; 10: 193-202.
10. Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M. How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer 2003; 10: 261-266.
11. Jiang SY, Jordan VC. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992; 84: 580-591.
12. Ali SH, O'Donnell AL, Mohamed S. Stable over-expression of estrogen receptor-alpha in ECV304 cells inhibits proliferation and levels of secreted endothelin-1 and vascular endothelial growth factor. Mol Cell Endocrinol 1999; 152: 1-9.
13. Tan H, Zhong Y, Pan Z. Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines. BMC Cancer 2009; 9: 31-42.
14. Zang XP, Pento JT. SiRNA inhibition of ER-alpha expression reduces KGF-induced proliferation of breast cancer cells. Anticancer Res 2008; 28: 2733-2735.
15. Fuckar D, Dekanic A, Stifter S, Mustać E, Krstulja M, Dobrila F, et al. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer. Int J Surg Pathol 2006; 14: 49-55.
16. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000; 19: 19-27.
17. O'Connor JK, Avent J, Lee RJ. Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 2004; 58: 1034-1040.
18. Badawi AF, Badr MZ. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer 2003; 103: 84-90.
19. Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer 2004; 4: 428-433.
20. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 2005; 26: 1393-1399.
21. Singh B, Berry JA, Vincent LE, Lucci A. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J Surg Res 2006; 134: 44-51.
22. Simeone AM, Nieves-Alicea R, McMurtry VC, Colella S, Krahe R, Tari AM. Cyclooxygenase-2 uses the protein kinase-C/interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells. Int J Oncol 2007; 30: 785-792.
23. Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 2001; 66: 159-164.
24. Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, et al. Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 2003; 16: 309-314.
25. Krishnan J, Kirkin V, Steffen A, Hegen M, Weih D, Tomarev S, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 2003; 63: 713-722.
26. Shi X, Chen G, Xing H, Weng D, Bai X, Ma D. VEGF-C, VEGFR-3, and COX-2 enhances growth and metastasis of human cervical carcinoma cell lines in vitro. Oncol Rep 2007; 18: 241-247.
27. Sun P, Gao J, Liu YL, Wei LW, Wu LP, Liu ZY. RNA interference (RNAi)-mediated vascular endothelial growth factor-C (VEGF-C) reduction interferes with lymphangiogenesis and enhances epirubicin sensitivity of breast cancer cells. Mol Cell Biochem 2008; 308: 161-168.
28. Wang XY, Tan JX, Vasse M, Delpech B, Ren GS. Comparison of hyaluronidase expression, invasiveness and tubule formation promotion in ER (-) and ER (+) breast cancer cell lines in vitro. Chin Med J 2009; 122: 1300-1304.
29. Timoshenko AV, Chakraborty C, Wagner GF, Lala PK. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 2006; 94: 1154-1163.
30. Zhang XH, Huang DP, Guo GL, Chen GR, Zhang HX, Wan L, et al. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer 2008; 8: 4-12.